Neuronal acetylcholine receptor subunit beta-2 (CHRNB2), Recombinant Protein

For Research Use Only. Not for use in diagnostic procedures.

Cell Free Expression

Liquid containing glycerol

Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.
Repeated freezing and thawing is not recommended. Store working aliquots at 4 degree C for up to one week.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of CHRNB2 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Transmembrane Protein

This is a recombinant transmembrane protein expressed in a cell-free expression system.

57,019 Da

cholinergic receptor nicotinic beta 2 subunit

neuronal acetylcholine receptor subunit beta-2

Neuronal acetylcholine receptor subunit beta-2

ACHB2_HUMAN

Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]

nAChRB2: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNB2 are the cause of nocturnal frontal lobe epilepsy type 3 (ENFL3). ENFL3 is an autosomal dominant epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta- 2/CHRNB2 sub-subfamily.

Protein type: Channel, cation; Channel, ligand-gated; Membrane protein, integral; Receptor, misc.; Membrane protein, multi-pass

Chromosomal Location of Human Ortholog: 1q21.3

Cellular Component: cell junction; external side of plasma membrane; integral to membrane; nicotinic acetylcholine-gated receptor-channel complex; plasma membrane; postsynaptic membrane

Molecular Function: acetylcholine binding; acetylcholine receptor activity; drug binding; ligand-gated ion channel activity; nicotinic acetylcholine-activated cation-selective channel activity; protein binding; protein heterodimerization activity

Biological Process: associative learning; B cell activation; behavioral response to nicotine; calcium ion transport; central nervous system projection neuron axonogenesis; cognition; conditioned taste aversion; ion transport; lateral geniculate nucleus development; learning; locomotory behavior; membrane depolarization; memory; negative regulation of action potential; neurological system process; neuromuscular synaptic transmission; optic nerve morphogenesis; positive regulation of B cell proliferation; positive regulation of dopamine secretion; positive regulation of synaptic transmission, dopaminergic; protein heterooligomerization; regulation of action potential; regulation of circadian sleep/wake cycle, non-REM sleep; regulation of circadian sleep/wake cycle, REM sleep; regulation of dendrite morphogenesis; regulation of dopamine metabolic process; regulation of dopamine secretion; regulation of synaptic transmission, dopaminergic; regulation of synaptogenesis; response to cocaine; response to ethanol; response to hypoxia; response to nicotine; sensory perception of pain; sensory perception of sound; signal transduction; smooth muscle contraction; social behavior; synaptic transmission involved in micturition; synaptic transmission, cholinergic; vestibulocochlear nerve development; visual learning; visual perception

Disease: Epilepsy, Nocturnal Frontal Lobe, 3

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.